Sign up to save your podcasts
Or
Share No pain, no gain: Ozempic’s quest for market share
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
No pain, no gain: Ozempic’s quest for market share
The shock success of GLP-1 treatments for obesity carries massive implications for wealthy societies and manufacturers Novo Nordisk and Eli Lilly alike. In this week’s Viewsroom podcast, Breakingviews columnists discuss how this would-be jackpot has companies running to keep up.
Visit the Thomson Reuters Privacy Statement for information on our privacy and data protection practices. You may also visit megaphone.fm/adchoices to opt-out of targeted advertising.
Learn more about your ad choices. Visit megaphone.fm/adchoices
View all episodes
By Reuters
4.2
4545 ratings
The shock success of GLP-1 treatments for obesity carries massive implications for wealthy societies and manufacturers Novo Nordisk and Eli Lilly alike. In this week’s Viewsroom podcast, Breakingviews columnists discuss how this would-be jackpot has companies running to keep up.
Visit the Thomson Reuters Privacy Statement for information on our privacy and data protection practices. You may also visit megaphone.fm/adchoices to opt-out of targeted advertising.
Learn more about your ad choices. Visit megaphone.fm/adchoices
More shows like Viewsroom
View all
NPR News Now
14,428 Listeners
Marketplace Morning Report
922 Listeners
WSJ Your Money Briefing
1,708 Listeners
Bloomberg Intelligence
397 Listeners
Bloomberg Businessweek
426 Listeners
Trumponomics
353 Listeners
WSJ Tech News Briefing
1,643 Listeners
The Big View
29 Listeners
Up First from NPR
56,575 Listeners
Bold Names
1,453 Listeners
Consider This from NPR
6,406 Listeners
The Big Take
157 Listeners
Reuters World News
279 Listeners
WSJ's Take On the Week
145 Listeners
Reuters Econ World
28 Listeners